1:00 PM ET | noon CT | 11:00 AM MT | 10:00 AM PT
Please join FSHD Society and Fulcrum Therapeutics in a community webinar announcing REACH, the 1st Phase 3 clinical trial in FSHD. REACH will enroll ~230 patients at clinical sites in US, Canada and Europe beginning this spring. Information regarding trial design and activation will be provided. Speakers will include FSHD Society Leadership along with Judy Dunn, President of Research and Development, Fulcrum Therapeutics.